<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04714177</url>
  </required_header>
  <id_info>
    <org_study_id>SIM23-ICH-201</org_study_id>
    <nct_id>NCT04714177</nct_id>
  </id_info>
  <brief_title>Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage</brief_title>
  <acronym>ED-ICH</acronym>
  <official_title>Efficacy and Safety of Edaravone Dexborneol in Addition to Standard of Care in Patients With Hypertensive Intracerebral Hemorrhage: a Randomized, Double-Blind, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu Simcere Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      pending&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportionof Participants With modified Rankin Scale (mRS) 0 ~ 1</measure>
    <time_frame>90 days after the first dose of study treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of death</measure>
    <time_frame>90 days after the first dose of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportionof Participants With modified Rankin Scale (mRS)</measure>
    <time_frame>14, 30 and 90 days after the first dose of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the NIH stroke scale (NIHSS) from the baseline</measure>
    <time_frame>14, 30 and 90 days after the first dose of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportionof Participants With Glasgow Outcome Score (GOS)</measure>
    <time_frame>14, 30 and 90 days after the first dose of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index (BI)</measure>
    <time_frame>90 days after the first dose of study treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke Specific Quality of Life Scale (SS-QOL)</measure>
    <time_frame>90 days after the first dose of study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Edaravone Dexborneol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Edaravone Dexborneol injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Edaravone Dexborneol matching injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edaravone Dexborneol</intervention_name>
    <description>Edaravone Dexborneol 37.5 mg, containing Edaravone 30 mg and Dexborneol 7.5 mg, Edaravone Dexborneol 37.5 mg BID, 14 days, addition to standard of care of Intracerebral Hemorrhage</description>
    <arm_group_label>Edaravone Dexborneol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Edaravone Dexborneol matching injection, addition to standard of care of Intracerebral Hemorrhage</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent from the patient or legally acceptable representative&#xD;
&#xD;
          -  Males and females&#xD;
&#xD;
          -  Diagnose as hypertensive intracerebral hemorrhage&#xD;
&#xD;
          -  Onset of symptoms within 6~48 hours&#xD;
&#xD;
          -  Position of bleeding major in basal ganglia&#xD;
&#xD;
          -  The sum of scores on items 5 and 6 on the NIHSS were &gt;= 2 at baseline and the total&#xD;
             score (items 1-11) was &gt;=6 and &lt;=20&#xD;
&#xD;
          -  Volume of Hematoma &lt;= 30 ml&#xD;
&#xD;
          -  Premorbid mRS score of 0 or 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to known study drugs or excipients&#xD;
&#xD;
          -  Experienced stroke in latest 3 month&#xD;
&#xD;
          -  Volume of Hematoma &gt; 5 ml in other bleeding position&#xD;
&#xD;
          -  Obstructive hydrocephalus&#xD;
&#xD;
          -  Any diagnosis as other than hypertensive ICH&#xD;
&#xD;
          -  Unconsciousness&#xD;
&#xD;
          -  Severe concurrent illness with life expectancy less than 90 days&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaofei Feng, MD</last_name>
    <phone>+86 18601203770</phone>
    <email>xiaofeimed@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaofei Feng, MD</last_name>
    <phone>+86(25)8556 6366</phone>
  </overall_contact_backup>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2021</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Jinsheng Zeng, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Intracranial Hemorrhage, Hypertensive</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edaravone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

